-
to tangible improvements in patient survival, which has improved little over the last 40 years. Most patients receive surgical resection followed by DNA damaging radiotherapy and temozolomide
-
stipend enhancement of £3,750 per year. Start date We are seeking applicants to start in September 2024. A later start date may be possible for the right applicant. The applicant Applications are welcome
Enter an email to receive alerts for DateCreated Last 7 Days positions